The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes

Abstract

Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria.

Keywords

IrbesartanMedicineMicroalbuminuriaAlbuminuriaDiabetic nephropathyInternal medicineType 2 diabetesDiabetes mellitusHazard ratioPlaceboNephropathyEndocrinologyUrologyConfidence intervalBlood pressure

Affiliated Institutions

Related Publications

[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].

Hans‐Henrik Parving , Hendrik Lehnert , Jens Brøchner‐Mortensen +3 more

Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria. It is safe and well tolerated.

2001 PubMed 2528 citations

Effective Postponement of Diabetic Nephropathy With Enalapril in Normotensive Type 2 Diabetic Patients With Microalbuminuria

Jamal Ahmad , Mohammad A. Siddiqui , Habib Ahmad

OBJECTIVE This study determines the long-term efficacy of the ACE inhibitor, enalapril, in reducing the progression of microalbuminuria to clinical albuminuria in normotensive p...

1997 Diabetes Care 197 citations

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner , Silvio E. Inzucchi , John M. Lachin +7 more

In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal...

2016 New England Journal of Medicine 3470 citations

Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients

Mordchai Ravid

In normotensive patients with diabetes mellitus type II, the institution of angiotensin-converting enzyme inhibition during early stages of diabetic nephropathy results in long-...

1993 Annals of Internal Medicine 784 citations

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( <scp>CANVAS‐R</scp> ): A randomized, placebo‐controlled trial

Bruce Neal , Vlado Perkovic , David R. Matthews +10 more

Aims The primary aim of the CANagliflozin cardioVascular Assessment Study‐Renal (CANVAS‐R) is to determine whether the favourable effects of inhibition of the sodium glucose co‐...

2017 Diabetes Obesity and Metabolism 160 citations

Publication Info

Year: 2001
Type: article
Volume: 345
Issue: 12
Pages: 870-878
Citations: 2861
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2861

OpenAlex

Cite This

APA Style

                            
                                
                                    Masanori Wakisaka, 
                                
                                    Hendrik Lehnert, 
                                
                                    Jens Brøchner‐Mortensen
                                
                                et al.
                            
                            (2001). 
                            The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes. 
                            New England Journal of Medicine
                            , 345
                            (12)
                            , 870-878.
                            https://doi.org/10.1056/nejmoa011489
                        

Identifiers

DOI: 10.1056/nejmoa011489